Gordon Cook

1 month ago | nature.com | Philippe Moreau |Katja Weisel |Hartmut Goldschmidt |Saad Usmani |Robert Orlowski |Nizar Bahlis | +7 more

AbstractIn the MAIA study, daratumumab plus lenalidomide and dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). We report updated efficacy and safety from MAIA (median follow-up, 64.5 months), including a subgroup analysis by patient age (<70, ≥70 to <75, ≥75, and ≥80 years).

Jan 8, 2024 | nature.com | Gordon Cook |David Cairns |John A Snowden

Minimal residual disease (MRD) is a reproducible and independent predictor of both progression-free (PFS) and overall (OS) survival in multiple myeloma [1]. These data along with ever improving survival outcomes has led to consideration of MRD as a potential surrogate end point for regulatory purposes and an appropriate endpoint in academic studies which could accelerate evaluation of novel agents [2].

Oct 28, 2023 | anguscountyworld.co.uk | Gordon Cook

Forfar Boys' Brigade marching from the Academy in a year that couldn't have been much later than the early 1960s. Does anyone know who owned the Austin, YS3772? Another chance to see photos from our archives and what was making the pages of the local newspapers back in the day